Verona Pharma Plc ADR [NASDAQ: VRNA] loss -0.15% or -0.16 points to close at $104.67 with a heavy trading volume of 15623741 shares.
It opened the trading session at $104.85, the shares rose to $104.91 and dropped to $104.58, the range by which the price of stock traded the whole day. The daily chart for VRNA points out that the company has recorded 126.56% gains over the past six months.
If we look at the average trading volume of 2.75M shares, VRNA reached to a volume of 15623741 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Verona Pharma Plc ADR [VRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VRNA shares is $106.30 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VRNA stock is a recommendation set at 2.83. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Verona Pharma Plc ADR shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 14, 2025. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Outperform. The new note on the price target was released on July 01, 2025, representing the official price target for Verona Pharma Plc ADR stock. Previously, the target price had yet another raise to $100, while TD Cowen analysts kept a Buy rating on VRNA stock.
The Price to Book ratio for the last quarter was 39.32, with the Price to Cash per share for the same quarter was set at 4.72.
Trading performance analysis for VRNA stock
Verona Pharma Plc ADR [VRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.77. With this latest performance, VRNA shares gained by 16.24% in over the last four-week period, additionally plugging by 126.56% over the last 6 months – not to mention a rise of 125.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VRNA stock in for the last two-week period is set at 70.47, with the RSI for the last a single of trading hit 3.71, and the three-weeks RSI is set at 3.65 for Verona Pharma Plc ADR [VRNA]. The present Moving Average for the last 50 days of trading for this stock 83.76, while it was recorded at 101.20 for the last single week of trading, and 57.97 for the last 200 days.
Verona Pharma Plc ADR [VRNA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Verona Pharma Plc ADR [VRNA] shares currently have an operating margin of -116.50% and a Gross Margin at 94.03%. Verona Pharma Plc ADR’s Net Margin is presently recorded at -138.52%.
Return on Equity for this stock declined to -40.26%, with Return on Assets sitting at -40.26%.
An analysis of Institutional ownership at Verona Pharma Plc ADR [VRNA]
There are presently around $90.98%, or 101.54% of VRNA stock, in the hands of institutional investors. The top three institutional holders of VRNA stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 7.63 million shares, which is approximately 1.1775%. MORGAN STANLEY, holding 0.86 million shares of the stock with an approximate value of $$12.49 million in VRNA stocks shares; and MORGAN STANLEY, currently with $$80.76 million in VRNA stock with ownership which is approximately 0.8616%.
